An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease

Published:2021-12-02 Issue:12 Volume:17 Page:1353-1361
ISSN:1742-5255
Container-title:Expert Opinion on Drug Metabolism & Toxicology
language:en
Short-container-title:Expert Opinion on Drug Metabolism & Toxicology

Author:

Tomlinson Brian¹^ORCID,Chow Elaine²^ORCID,Chan Paul³^ORCID,Lam Christopher Wai Kei¹^ORCID

Affiliation:

1. Faculty of Medicine, Macau University of Science and Technology, Macau, China

2. Department of Medicine and Therapeutics, Prince of Wales Hospital, the Chinese University of Hong Kong, Hong Kong SAR, China

3. Division of Cardiovascular Medicine, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei City, Taiwan

Funder

Faculty of Medicine, Macau University of Science and Technology

Publisher

Informa UK Limited

Subject

Pharmacology,Toxicology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17425255.2021.2029402

Reference64 articles.

1. Heart Disease and Stroke Statistics—2021 Update

2. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

3. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

4. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

5. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The changing landscape of drug clinical trials on cardiometabolic diseases in China, 2009–2021;Diabetology & Metabolic Syndrome;2023-04-01

2. Effectiveness and safety of Inclisiran in hyperlipidemia treatment: An overview of systematic reviews;Medicine;2023-01-20

3. Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9;Pharmaceutics;2023-01-18

4. The therapeutic prospects of N-acetylgalactosamine-siRNA conjugates;Frontiers in Pharmacology;2022-12-14

5. New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy;Russian Journal of Cardiology;2022-12-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3